Neko, Prenuvo or YEARS: the three ways to get checked in Europe

Until recently a European wanting a serious private health check had two options: a German or Swiss clinic, or a flight. Neko opened in Stockholm and London, Prenuvo opened in London in 2025, and Berlin built something that does not exist anywhere else at the price. The three are now genuinely available and almost never compared properly, because comparing them requires admitting they are not alternatives.

The contents, side by side

Neko Health, £299 in the UK, about 60 minutes. A proprietary optical scanner covering the whole skin surface, a cardiovascular sensor array, and a blood panel, running to roughly 70 datapoints. No imaging. Over 100,000 examinations completed, and around three-quarters of members prepay their next annual visit.1

Prenuvo, from $1,199 a year. Core buys a focused MRI and a lab panel; Comprehensive at $2,499 buys the whole-body scan with detailed labs; Executive at close to $5,000 adds brain health and body composition.2 Over 170,000 scans across 29 clinics, with London the first European site. The focused scan at the entry tier excludes spine and limbs, which is the detail most worth checking against the tier you are quoted.

YEARS, €1,900 to €16,900, one day of six to nine hours in Berlin, across three tiers that gate modalities rather than only depth. Core at €1,900 buys 87 biomarkers with spiroergometry, echocardiography, vascular ultrasound, a cognition test, lung function and body composition, and contains no imaging, no liquid biopsy and no genetics. Evolve at €7,600 adds 3T whole-body MRI and a multi-cancer liquid biopsy at 120-plus biomarkers, with one annual check-in. Ultimate at €16,900 adds genome sequencing, epigenetic clocks and microbiome analysis at 230-plus, with three check-ins.3

What only one of them has

Genomics, a liquid biopsy and a cardiopulmonary exercise test appear only in the YEARS programme. That matters differently for each.

The gene panel is a once-in-a-lifetime measurement, which makes bundling it into a single baseline visit sensible rather than wasteful. The liquid biopsy is the most defensible recent addition to preventive screening on the evidence, holding our grade B- after PATHFINDER 2. Ergospirometry is the best-evidenced measurement in the whole category and the one we grade highest at B, and its inclusion in the €1,900 entry programme rather than a premium tier is the detail we would weight most heavily if choosing.

Whole-body MRI appears in Prenuvo’s higher tiers and, at YEARS, from Evolve at €7,600 upward rather than in the €1,900 entry programme. Our assessment of it remains grade C, meaning no randomised trial has shown net benefit in asymptomatic adults,5 so its presence is not automatically a point in a programme’s favour, and its absence from an entry tier is not automatically a gap. What differs between the two is the apparatus: Prenuvo delivers a radiologist report inside an imaging business, while YEARS reads the image next to the bloods, the function testing and the history on the same day, which is the arrangement that handles an incidental finding better.

Nothing in Neko’s product requires any leap of faith about screening efficacy, which is the quiet strength of the cheapest option. Blood pressure, lipids, glucose and skin surveillance have decades of outcome evidence behind them. Neko measures the well-evidenced things and declines the rest, at a price that makes annual attendance realistic. It is the most conservative product in the category and the only one designed to be repeated indefinitely.

Neko is priced to be a habit. YEARS is priced to be a baseline. Prenuvo is priced to be an image. Buying one to do another one’s job is how people waste money here.

The price comparison that is fair

Comparing £299 with €1,900 as though they buy the same thing is meaningless. Two narrower comparisons are informative.

For a whole-body MRI specifically, the comparison is Prenuvo’s Comprehensive tier at $2,499 against YEARS Evolve at €7,600, since Evolve is the cheapest YEARS tier containing imaging. Evolve costs roughly three times as much and includes a multi-cancer liquid biopsy, ergospirometry, multi-region ultrasound and 120-plus biomarkers alongside the scan, none of which Prenuvo offers at any tier. If the scan is the only thing you want, Prenuvo is substantially cheaper. For unbundled context, OneMRI in Australia sells the scan alone at A$2,990, which suggests how much of any bundled price is imaging and how much is everything else.

For annual monitoring, Neko at £299 has no competitor in this group. Prenuvo’s Core membership at $1,199 is four times the price for a narrower set of well-evidenced measurements plus a focused scan. YEARS is not designed for annual repetition and does not price itself that way.

Who each is actually for

Neko suits somebody healthy, under 45, without a family history that keeps them awake, who wants a trend line and will realistically show up every year. It is also the right first purchase for anyone who has never had a proper check, because it is cheap enough that the decision is easy.

Prenuvo suits somebody whose specific concern is anatomical, often a family history of a cancer that imaging can find, who has thought about the incidental finding rate and accepted it. It suits people who want the scan and do not want the rest of a clinic visit attached.

YEARS suits somebody who wants one comprehensive baseline read by a physician in a single day, particularly around the point in life where family history stops being abstract. Which tier depends on the question. Core at €1,900 is a functional and laboratory workup and the only entry tier in our Index that leads with the measurement we grade highest while omitting the one we grade C. Evolve at €7,600 is the cheapest programme anywhere in the Index containing both whole-body MRI and a multi-cancer blood test, against $15,000 for the comparable American tier. Read the tier rather than the range: the spread from €1,900 to €16,900 is not depth of the same thing, it is different things.

The sequence, if you want one

One multi-modal baseline, reasonably early, read by a clinician who owns the follow-up. Cheap annual monitoring after that. Repeat imaging only when something indicates it rather than on a calendar.

That sequence uses each of these products for what it is good at, and it costs less over a decade than any of the annual premium memberships. None of the three companies will recommend it, because it involves buying from two of their competitors.